Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Other financing activities (2017 - 2023)

PharmaCyte Biotech (PMCB) has disclosed Other financing activities for 10 consecutive years, with $2.3 million as the latest value for Q3 2023.

  • On a quarterly basis, Other financing activities rose 82211.45% to $2.3 million in Q3 2023 year-over-year; TTM through Jul 2023 was $2.3 million, a 9030.67% increase, with the full-year FY2023 number at $7334.0, down 77.87% from a year prior.
  • Other financing activities was $2.3 million for Q3 2023 at PharmaCyte Biotech, up from $667.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.3 million in Q3 2023 to a low of $667.0 in Q1 2023.
  • A 5-year average of $165341.4 and a median of $48187.5 in 2019 define the central range for Other financing activities.
  • Biggest YoY gain for Other financing activities was 82211.45% in 2023; the steepest drop was 91.95% in 2023.
  • PharmaCyte Biotech's Other financing activities stood at $104727.0 in 2019, then crashed by 35.72% to $67320.0 in 2020, then plummeted by 83.58% to $11055.0 in 2021, then plummeted by 64.57% to $3917.0 in 2022, then skyrocketed by 57688.23% to $2.3 million in 2023.
  • Per Business Quant, the three most recent readings for PMCB's Other financing activities are $2.3 million (Q3 2023), $667.0 (Q1 2023), and $3917.0 (Q4 2022).